|Bid||13.03 x 800|
|Ask||13.36 x 1100|
|Day's Range||12.52 - 13.55|
|52 Week Range||9.39 - 35.73|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.33|
SAN DIEGO, August 09, 2022--Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Janux Therapeutics, Inc. ( NASDAQ:JANX ) shareholders should be happy to see the share price up 13% in the last month...
SAN DIEGO, June 02, 2022--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the 2022 Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 11:00 a.m. ET in New York, New York.